CARE II - Evaluation of treatment outcomes in schizophrenic patients taking part in the integrated care program - a single-country, multi-centre phase IV study

Update Il y a 4 ans
Reference: EUCTR2007-007127-40

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Primary study objective is to assess the effect of quetiapine XR with or without concomitant participation in the ICP on the subjective well-being in patients treated for symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified, measured by the patients' self-report instrument SWN-K total score with a result of ≥ 80 defined as the response limit for an adequate subjective well-being over a study treatment period of 18 months.


Inclusion criteria

  • Symptomatic schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder or psychotic disorder not otherwise specified

Links